SCHEMBL2632866

SCHEMBL2632866

CNC(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.73
KMT2A Q03164 3/20 0.73
MEN1 O00255 2/20 0.73
HTT P42858 1/20 0.73
RAB9A P51151 1/20 0.73
ALDH1A1 P00352 1/20 0.71
SMN1; SMN2 Q16637 2/20 0.65
KDM4E B2RXH2 1/20 0.65
TP53 P04637 2/20 0.65
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA9 Q16790 1/20 0.61
GAA P10253 1/20 0.61
KDR P35968 1/20 0.61
LMNA P02545 1/20 0.60
MAPK1 P28482 1/20 0.60
GRIK1 P39086 2/20 0.59
EPHX2 P34913 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5597699 0.90 KMT2A (0.90) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL30101230 0.90 KMT2A (0.90) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL4548162 0.88 KMT2A (0.87) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL22024980 0.85 KMT2A (0.77) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL30069239 0.85 MAPT (1.00) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL13155174 0.85 HDAC8 (0.59) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL17609423 0.85 MAPT (1.00) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL17664317 0.85 KMT2A (0.81) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL26416486 0.85 MAPT (0.76) MAPTKMT2AMEN1HTTRAB9A
SCHEMBL10192109 0.84 KMT2A (0.74) MAPTKMT2AMEN1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675858-B1 IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION OPTIKIRA LLC (US) 2023-04-26 EP disclosed
WO-2021072028-A1 ACTIVATORS OF HEME REGULATED INHIBITOR KINASE (HRI) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-04-15 WO disclosed
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-11-03 US disclosed
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-11-03 US disclosed
US-9421211-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-08-23 US disclosed
US-9421211-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-08-23 US disclosed
US-9040516-B2 Uracil derivative and use thereof for medical purposes SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-05-26 US disclosed
US-9040516-B2 Uracil derivative and use thereof for medical purposes SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-05-26 US disclosed
US-9040516-B2 Uracil derivative and use thereof for medical purposes SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-05-26 US disclosed
CN-104024241-A Uracil derivatives and their use for medical purposes DAINIPPON SUMITOMO PHARMA CO 2014-09-03 CN disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
WO-2012002502-A1 DIHYDROPYRIMIDINONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF 大日本住友製薬株式会社 (JP) 2012-01-05 WO disclosed
US-7989422-B2 Antibacterial agents ALCHEMIA LIMITED (AU) 2011-08-02 US disclosed
WO-2010138820-A2 N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-02 WO disclosed
EP-2076260-A1 N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2009-07-08 EP disclosed
US-20090023669-A1 Antibacterial Agents ALCHEMIA LIMITED (AU) 2009-01-22 US disclosed
WO-2008033567-A1 N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-03-20 WO disclosed
US-4435567-A REACTING AN AMINE WITH AN N-CARBAMOYL BENZOIC ACID SULFIMIDE CHINOIN GYOGYSZER ES VESGYESZETI TERMEKEK GYARA R. T. (HU) 1984-03-06 US disclosed
US-4045209-A Substituted ureas as herbicides ROUSSEL UCLAF (FR) 1977-08-30 US disclosed
US-3978123-A HERBICIDAL N-ALKYLSULFOXYMETHYL-AND-N-ALKYLSULFONYL-METHYL-N-ARYL CHEVRON RESEARCH COMPANY (US) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation NSUN2, EIF2AK2, RNGTT MAPT 1631/4885KMT2A 761/4885MEN1 2936/4885
US-20090023669-A1 Antibacterial Agents MRPL21, FUT6, FUT5 MAPT 4853/4885KMT2A 4563/4885MEN1 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.